US 12,285,357 B2
Intraocular drug delivery systems and methods of use
Craig Alan Cable, II, Aliso Viejo, CA (US); Malik Y. Kahook, Denver, CO (US); Ryan Absalonson, Aliso Viejo, CA (US); and Glenn R. Sussman, Aliso Viejo, CA (US)
Assigned to SpyGlass Pharma, Inc., Aliso Viejo, CA (US); and The Regents of the University of Colorado, a body corporate, Denver, CO (US)
Filed by SpyGlass Pharma, Inc., Aliso Viejo, CA (US); and The Regents of the University of Colorado, Denver, CO (US)
Filed on Jul. 20, 2023, as Appl. No. 18/356,133.
Application 18/356,133 is a continuation of application No. PCT/US2023/070625, filed on Jul. 20, 2023.
Claims priority of provisional application 63/500,231, filed on May 4, 2023.
Claims priority of provisional application 63/391,399, filed on Jul. 22, 2022.
Prior Publication US 2024/0024158 A1, Jan. 25, 2024
Int. Cl. A61F 9/00 (2006.01); A61F 2/16 (2006.01); A61F 9/007 (2006.01)
CPC A61F 9/0017 (2013.01) [A61F 2/16 (2013.01); A61F 2/1601 (2015.04); A61F 2002/1681 (2013.01); A61F 2002/1689 (2013.01); A61F 2002/16901 (2015.04); A61F 2/1691 (2013.01); A61F 9/00781 (2013.01); A61F 2210/00 (2013.01); A61F 2250/0068 (2013.01)] 31 Claims
OG exemplary drawing
 
1. A method of delivering at least one therapeutic agent to an eye of a subject, the method comprising:
implanting a drug delivery component into the eye and adjacent to a fluid-permeable membrane of the eye of the subject, the drug delivery component comprising a solid non-bioerodible drug core and a solid non-bioerodible membrane encapsulating the solid non-bioerodible drug core, the solid non-bioerodible drug core comprising the at least one therapeutic agent embedded within a biocompatible polymer; and
eluting by diffusion the at least one therapeutic agent from the solid non-bioerodible drug core through the solid non-bioerodible membrane and into the eye of the subject.